FDA Approves Self-Injection of Vyvgart Hytrulo
Approval granted for patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy
Tirzepatide Dispensations Increased Rapidly After Approval
By December 2023, 12.3 percent of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
Most common gastrointestinal issues seen are nausea/vomiting, abdominal pain, and diarrhea
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury
FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer
The CheckMate-9DW trial showed significant overall survival benefit versus lenvatinib or sorafenib
Brain Functional Networks Affected by Neoadjuvant Chemo in Breast Cancer
Increased global efficiency, as well as decreased characteristic path length and altered nodal centralities, seen on functional MRI
FDA Announces Plan to Phase Out Some Animal Testing
New strategy aims to enhance drug safety, expedite evaluation process, and decrease animal experimentation
CDC Urges Extra Measles Shot for Some U.S. Travelers Amid Outbreak
FDA Reverses Office Order, Lets Staff Work From Home
2018 to 2022 Saw Increase in GLP-1 Receptor Agonist Use in Adults Without Diabetes
Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022
